ARCHIVES

CMS also decided to cover off-label uses of approved colorectal cancer drugs in clinical trials, and allowed broader use of PET scans.

This article is from The Cancer Letter archive.

Vol. 30 No. 42 | November 5, 2004

Download PDF Visit The Full Archive

Related Articles

Daily Aspirin May Reduce Risk By 20 Percent, Study Says

February 28, 2014

Former NCI, FDA Chief Andrew Von Eschenbach Appointed to NCCN Foundation Board

June 17, 2011

AACR 2014 Cancer Progress Report: More Federal Funds Needed

September 19, 2014

Breast Treatment Component Will Be Planned for WHI

June 21, 1991

Coalition Demands Role In Deciding spending will Target Healy, Broder, Chabner

October 16, 1992

Senate Gives NIH Director Authority To Permit Research By Unconventional MDs

September 25, 1992